Spero Therapeutics (SPRO) to Release Quarterly Earnings on Wednesday

Spero Therapeutics (NASDAQ:SPRO) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Tuesday, May 13th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.30. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%. The company had revenue of $5.87 million for the quarter, compared to analyst estimates of $11.00 million. On average, analysts expect Spero Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Spero Therapeutics Stock Performance

SPRO stock opened at $0.69 on Tuesday. Spero Therapeutics has a 52 week low of $0.51 and a 52 week high of $1.60. The firm’s fifty day moving average is $0.69 and its 200 day moving average is $0.88. The firm has a market cap of $38.54 million, a P/E ratio of 9.85 and a beta of 0.23.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a report on Thursday, January 30th.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.